MABs Therapy m.3243A>G Mutation Carriers

计划入组 6 人 · 首次发布于 2021 年 10 月 1 日

Effect and Safety MABs Administration m.3243A>G Mutation Carriers

计划入组 20 人 · 首次发布于 2023 年 7 月 27 日

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

计划入组 18 人 · 首次发布于 2022 年 2 月 15 日

QRX-036

G-44

G-3215

G&G MEDICAL INC

United States

BATEMAN, TIMOTHY M. M. MD

United States

ARNAS G. BROTZU

Italy

Khondrion's Sonlicromanol Receives FDA Clearance for Phase 3 Trial in Primary Mitochondrial Disease

Khondrion's Sonlicromanol Receives FDA Clearance for Phase 3 Trial in Primary Mitochondrial Disease

Mito Fund Invests in Khondrion to Advance Sonlicromanol for Primary Mitochondrial Disease